A 5-MicroRNA Signature Identified from Serum MicroRNA Profiling Predicts Survival in Patients with Advanced Stage Non-Small Cell Lung Cancer. Zhang Y1,2, Roth JA3, Yu H1, et al. Carcinogenesis. 2018 Nov 14. doi: 10.1093/carcin/bgy132. [Epub ahead of print]

miR-181b/Notch2 overcome chemoresistance by regulating cancer stem cell-like properties in NSCLC. Wang X1, Meng Q1, Qiao W2, Ma R1, Ju W3, Hu J1, Lu H1, Cui J1, Jin Z1, Zhao Y4, Wang Y5. Stem Cell Res Ther. 2018 Nov 23;9(1):327. doi: 10.1186/s13287-018-1072-1.

H3K9 methyltransferases and demethylases control lung tumor-propagating cells and lung cancer progression. Rowbotham SP1,2, Li F3, Dost AFM1,2, et al. Nat Commun. 2018 Nov 19;9(1):4559. doi: 10.1038/s41467-018-07077-1.

VCAM-1 targeted magnetic resonance imaging enables detection of brain micrometastases from different primary tumours. Cheng VWT1, Sarmiento Soto M2, Khrapitchev AA1, et al. Clin Cancer Res. 2018 Nov 2. pii: clincanres.1889.2018. doi: 10.1158/1078-0432.CCR-18-1889. [Epub ahead of print]

Expert knowledge-infused deep learning for automatic lung nodule detection. Tan J1, Huo Y2, Liang Z3, Li L4. J Xray Sci Technol. 2018 Nov 15. doi: 10.3233/XST-180426. [Epub ahead of print]

Machine learning to predict lung nodule biopsy method using CT image features: A pilot study. Sumathipala Y1, Shafiq M2, Bongen E3, Brinton C4, Paik D5. Comput Med Imaging Graph. 2018 Nov 3;71:1-8. doi: 10.1016/j.compmedimag.2018.10.006. [Epub ahead of print]

Using a Smoking Cessation Quitline to Promote Lung Cancer Screening. Sharma A, Bansal-Travers M, Celestino P, Fine J, Reid ME, Hyland A, O’Connor R. Am J Health Behav. 2018 Nov 1;42(6):85-100. doi: 10.5993/AJHB.42.6.9.

Investigating unilateral pleural effusions: the role of cytology. Arnold DT1, De Fonseka D2, Perry S3, Morley A4, Harvey JE4, Medford A4, Brett M5, Maskell NA2. Eur Respir J. 2018 Nov 8;52(5). pii: 1801254. doi: 10.1183/13993003.01254-2018. Print 2018 Nov.

The decision to biopsy in a lung cancer screening program: Potential impact of risk calculators. Gilbert CR1, Carlson AS2, Wilshire CL1, Aye RW1, Farivar AS1, Bograd AJ1, Gorden JA1. J Med Screen. 2018 Nov 12:969141318811362. doi: 10.1177/0969141318811362. [Epub ahead of print]

The Landscape of US Lung Cancer Screening Services. Kale MS1, Wisnivesky J2, Taioli E3, Liu B4. Chest. 2018 Nov 9. pii: S0012-3692(18)32720-X. doi: 10.1016/j.chest.2018.10.039. [Epub ahead of print]

Financial analysis of free lung cancer screening program shows profitability using broader NCCN Guidelines. Chung JM1, Simmerman E1, Sadek R2, Wojtowicz S3, Dillard T4, Albo D5, Thomson N6, Schroeder C7. Ann Thorac Surg. 2018 Nov 9. pii: S0003-4975(18)31624-2. doi: 10.1016/j.athoracsur.2018.09.056. [Epub ahead of print]

Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. Kandathil A1, Kay FU1, Butt YM1, Wachsmann JW1, Subramaniam RM1. Radiographics. 2018 Nov-Dec;38(7):2134-2149. doi: 10.1148/rg.2018180060.

Lung cancer screening: Practice guidelines and insurance coverage are not enough. McDonnell KK1, Estrada RD1, Dievendorf AC1, Blew L1, Sercy E2, Khan S2, Hardin JW3, Warden D1, Eberth JM3. J Am Assoc Nurse Pract. 2018 Nov 9. doi: 10.1097/JXX.0000000000000096. [Epub ahead of print]

ACR Appropriateness Criteria® Lung Cancer Screening. Expert Panel on Thoracic Imaging:, Donnelly EF1, Kazerooni EA2, Lee E3, Henry TS4, Boiselle PM5, Crabtree TD6, Iannettoni MD7, Johnson GB8, Laroia AT9, Maldonado F10, Olsen KM11, Shim K12, Sirajuddin A13, Wu CC14, Kanne JP15. J Am Coll Radiol. 2018 Nov;15(11S):S341-S346. doi: 10.1016/j.jacr.2018.09.025.

The Case for Patient Navigation in Lung Cancer Screening in Vulnerable Populations: A Systematic Review. Shusted CS1, Barta JA2, Lake M2, et al. Popul Health Manag. 2018 Nov 8. doi: 10.1089/pop.2018.0128. [Epub ahead of print]

Early detection of lung cancer in a population at high risk due to occupation and smoking. Welch LS1, Dement JM2, Cranford K3, Shorter J3, Quinn PS1, Madtes DK4,5, Ringen K1. Occup Environ Med. 2018 Nov 10. pii: oemed-2018-105431. doi: 10.1136/oemed-2018-105431. [Epub ahead of print]

Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study. Folch EE1, Pritchett MA2, Nead MA3, et al. J Thorac Oncol. 2018 Nov 23. pii: S1556-0864(18)33456-7. doi: 10.1016/j.jtho.2018.11.013. [Epub ahead of print]

Patient-Physician Discussions on Lung Cancer Screening: A Missed Teachable Moment to Promote Smoking Cessation. Kathuria H1, Koppelman E2,3, Borrelli B4, Slatore CG5,6, Clark JA2,3, Lasser KE3,7, Wiener RS1,2. Nicotine Tob Res. 2018 Nov 23. doi: 10.1093/ntr/nty254. [Epub ahead of print]

Surgical Management of Lung Cancer: History, Evolution, and Modern Advances. Abbas AE1. Curr Oncol Rep. 2018 Nov 13;20(12):98. doi: 10.1007/s11912-018-0741-7.

Prognostic impact of underlying lung disease in pulmonary wedge resection for lung cancer. Kawaguchi T1, Sawabata N2, Miura S3, Kawai N2, Yasukawa M2, Tojo T2, Taniguchi S2. Int J Clin Oncol. 2018 Nov 15. doi: 10.1007/s10147-018-1367-3. [Epub ahead of print]

Right-sided vs Left-sided Pneumonectomy after Induction Therapy for Non-small-cell Lung Cancer. Yang CJ1, Shah S1, Lin BK1, et al. Ann Thorac Surg. 2018 Nov 15. pii: S0003-4975(18)31657-6. doi: 10.1016/j.athoracsur.2018.10.009. [Epub ahead of print]

Comparison between Stereotactic Radiotherapy and Sublobar Resection for Non-Small Cell Lung Cancer. Tamura M1, Matsumoto I2, Tanaka Y2, et al.  Ann Thorac Surg. 2018 Nov 17. pii: S0003-4975(18)31664-3. doi: 10.1016/j.athoracsur.2018.10.015. [Epub ahead of print]

Long-Term Prognostic Impact of Severe Postoperative Complications After Lung Cancer Surgery. Okada S1, Shimada J1, Kato D1, Tsunezuka H1, Teramukai S2, Inoue M3. Ann Surg Oncol. 2018 Nov 19. doi: 10.1245/s10434-018-7061-x. [Epub ahead of print]

Clinical outcomes of hypofractionated image-guided multifocal irradiation using volumetric-modulated arc therapy for brain metastases. Furutani S1, Ikushima H2, Sasaki M3, et al. J Radiat Res. 2018 Nov 16. doi: 10.1093/jrr/rry091. [Epub ahead of print]

Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer. Yoshida H1, Kim YH2, Ozasa H1, et al. In Vivo. 2018 Nov-Dec;32(6):1587-1590. doi: 10.21873/invivo.11418.

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. Soyano AE1, Dholaria B1,2, Marin-Acevedo JA3, et al. J Immunother Cancer. 2018 Nov 23;6(1):129. doi: 10.1186/s40425-018-0447-2.

Afatinib versus gemcitabine/cisplatin for first-line treatment of Chinese patients with advanced non-small-cell lung cancer harboring EGFR mutations: subgroup analysis of the LUX-Lung 6 trial. Wu YL1, Xu CR1, Hu CP2, et al. Onco Targets Ther. 2018 Nov 30;11:8575-8587. doi: 10.2147/OTT.S160358. eCollection 2018.

Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients. Davies J1, Martinec M2, Coudert M3, Delmar P2, Crane G1. Curr Med Res Opin. 2018 Nov 9:1-8. doi: 10.1080/03007995.2018.1533458. [Epub ahead of print]

Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting. Winfree KB1, Torres AZ2, Zhu YE1, Muehlenbein C1, Aggarwal H1, Woods S1, Abernethy A2. Curr Med Res Opin. 2018 Nov 13:1-25. doi: 10.1080/03007995.2018.1547273. [Epub ahead of print]

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Solomon BJ1, Besse B2, Bauer TM3, et al. .Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6.

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. Han B1, Li K2, Wang Q3,4, et al. JAMA Oncol. 2018 Nov 1;4(11):1569-1575. doi: 10.1001/jamaoncol.2018.3039.

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. Shin J1, Chung JH2, Kim SH1, et al. Cancer Res Treat. 2018 Nov 5. doi: 10.4143/crt.2018.537. [Epub ahead of print]

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Gadgeel S1, Peters S2, Mok T3, Shaw AT4, et al. Ann Oncol. 2018 Nov 1;29(11):2214-2222. doi: 10.1093/annonc/mdy405.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. Pennell NA1, Neal JW1, Chaft JE1, et al. J Clin Oncol. 2018 Nov 16:JCO1800131. doi: 10.1200/JCO.18.00131. [Epub ahead of print]

Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression. Chen RL1, Zhao J2, Zhang XC1, et al. BMC Cancer. 2018 Nov 26;18(1):1171. doi: 10.1186/s12885-018-5078-y.

Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC). Lichtenstein M1, Nipp RD1, Muzikansky A1, Goodwin K1, Anderson D1, Newcomb RA1, Gainor JF2. J Thorac Oncol. 2018 Nov 23. pii: S1556-0864(18)33454-3. doi: 10.1016/j.jtho.2018.11.011. [Epub ahead of print]

The impact of prophylactic cranial irradiation for post-operative patients with limited stage small cell lung cancer. Chen MY1,2, Hu X1, Xu YJ1, Chen M1. Medicine (Baltimore). 2018 Nov;97(44):e13029. doi: 10.1097/MD.0000000000013029.

Clinical outcomes of stereotactic body radiotherapy for de novo pulmonary tumors in patients with completely resected early stage non-small cell lung cancer. Zhao Q1, Chen G1, Ye L1, Zeng Z1, Shi S1, He J1. Cancer Manag Res. 2018 Nov 28;10:6391-6398. doi: 10.2147/CMAR.S180345. eCollection 2018.

The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. Starkov P1, Aguilera TA2, Golden DI3, et al. Br J Radiol. 2018 Nov 20:20180228. doi: 10.1259/bjr.20180228. [Epub ahead of print]

Design and validation of a MV/kV imaging-based markerless tracking system for assessing real-time lung tumor motion. Zhang P1, Hunt M1, Telles AB2, et al. Med Phys. 2018 Dec;45(12):5555-5563. doi: 10.1002/mp.13259. Epub 2018 Nov 13.

Doses of radiation to the pericardium, instead of heart, are significant for survival in patients with non-small cell lung cancer. Xue J1, Han C2, Jackson A3, et al. Radiother Oncol. 2018 Nov 8. pii: S0167-8140(18)33553-9. doi: 10.1016/j.radonc.2018.10.029. [Epub ahead of print]

Radiation and the heart: systematic review of dosimetry and cardiac endpoints. Niska JR1, Thorpe CS1, Allen SM2, Daniels TB1, Rule WG1, Schild SE1, Vargas CE1, Mookadam F2. Expert Rev Cardiovasc Ther. 2018 Dec;16(12):931-950. doi: 10.1080/14779072.2018.1538785. Epub 2018 Nov 1.

Treatment completion, treatment compliance and outcomes of old and very old patients treated by dose adapted stereotactic ablative radiotherapy (SABR) for T1-T3N0M0 non-small cell lung cancer. Mihai A1, Milano MT2, Santos A3, Kennedy AM4, Thirion P4, Rock L4, Westrup J3, McDermott R3, Armstrong JG4. Geriatr Oncol. 2018 Nov 10. pii: S1879-4068(18)30288-1. doi: 10.1016/j.jgo.2018.10.011. [Epub ahead of print]

Clinical outcomes following advanced respiratory motion management (respiratory gating or dynamic tumor tracking) with stereotactic body radiation therapy for stage I non-small-cell lung cancer. Aridgides P1, Nsouli T1, Chaudhari R1, et al. Lung Cancer (Auckl). 2018 Nov 5;9:103-110. doi: 10.2147/LCTT.S175168. eCollection 2018.

Phase II Study of Weekly Amrubicin for Refractory or Relapsed Small Cell Lung Cancer. Yoshioka H1,2,3, Kogure Y4,5, Ando M6, Kitagawa C4, Iwasaku M7,8, Niwa T7,9, Saka H4. In Vivo. 2018 Nov-Dec;32(6):1581-1586. doi: 10.21873/invivo.11417.

Impact of prophylactic cranial irradiation on pattern of brain metastases as a first recurrence site for limited-disease small-cell lung cancer. Nakamura M1, Onozawa M1, Motegi A1, et al. J Radiat Res. 2018 Nov 1;59(6):767-773. doi: 10.1093/jrr/rry066.

Paraneoplastic syndrome as the presentation of limited stage small cell carcinoma. Nikoomanesh K1, Choi J2, Arabian S2. BMC Pulm Med. 2018 Nov 14;18(1):169. doi: 10.1186/s12890-018-0729-y.

Palliative Care in Lung Cancer: When to Start. Bhattacharya P1, Dessain SK2, Evans TL3,4. Author information:  Curr Oncol Rep. 2018 Nov 9;20(11):90. doi: 10.1007/s11912-018-0731-9.

Clinical utility of portable electrophysiology to measure fatigue in treatment-naïve non-small cell lung cancer. O’Connor B1,2, Markicevic M3,4, Newman L3,4, Poduval RK3,4, Tiernan E5, Hanrahan E6, Cuffe S7, Reilly RB3,4,8, Walsh D9,8,10. Support Care Cancer. 2018 Nov 22. doi: 10.1007/s00520-018-4542-1. [Epub ahead of print]

Early Skeletal Muscle Loss in Non-Small Cell Lung Cancer Patients Receiving Chemoradiation and Relationship to Survival. Kiss N1,2,3, Beraldo J4, Everitt S4,5,6. Support Care Cancer. 2018 Nov 26. doi: 10.1007/s00520-018-4563-9. [Epub ahead of print]

NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients Iimura Y, Shimomura H, Yasu T, Imanaka K, Ogawa R, Ito A, Suzuki K, Yamaguchi G, Kawasaki N, Konaka C. Int J Clin Pharmacol Ther. 2018 Nov;56(11):551-554. doi: 10.5414/CP203323.

Prognostic Value of Patient Knowledge of Cancer on Quality of Life in Advanced Lung Cancer During Chemotherapy. Adamowicz K1, Janiszewska J2, Lichodziejewska-Niemierko M2,3. J Cancer Educ. 2018 Nov 12. doi: 10.1007/s13187-018-1444-3. [Epub ahead of print]

Study of the anti-allergic and anti-inflammatory activity of Brachychiton rupestris and Brachychiton discolor leaves (Malvaceae) using in vitro models. Thabet AA1, Youssef FS1, Korinek M2,3,4,5, et al. BMC Complement Altern Med. 2018 Nov 9;18(1):299. doi: 10.1186/s12906-018-2359-6.

Maintenance Chemotherapy With Chinese Herb Medicine Formulas vs. With Placebo in Patients With Advanced Non-small Cell Lung Cancer After First-Line Chemotherapy: A Multicenter, Randomized, Double-Blind Trial. Wang Q1, Jiao L1,2, Wang S3, et al. Front Pharmacol. 2018 Nov 6;9:1233. doi: 10.3389/fphar.2018.01233. eCollection 2018.

Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology. Bing Z1,2,3, Cheng Z1,2, Shi D4, et al. BMC Complement Altern Med. 2018 Nov 6;18(1):293. doi: 10.1186/s12906-018-2347-x.

Surveillance for Cancers Associated with Tobacco Use – United States, 2010-2014. Gallaway MS1,2, Henley SJ1, Steele CB1, et al. MMWR Surveill Summ. 2018 Nov 2;67(12):1-42. doi: 10.15585/mmwr.ss6712a1.

Impact of Perceived Stigma in People Newly Diagnosed With Lung Cancer: A Cross-Sectional Analysis. Rose S1, Kelly B1, Boyes A1, Cox M1, Palazzi K2, Paul C1. Oncol Nurs Forum. 2018 Nov 1;45(6):737-747. doi: 10.1188/18.ONF.737-747.

Primary care providers’ views on a future lung cancer screening program. (Canada) O’Brien MA1, Llovet D2,3, Sullivan F1,4,5,6, Paszat L4,7,8. Fam Pract. 2018 Nov 5. doi: 10.1093/fampra/cmy099. [Epub ahead of print]

Disparities in the Diagnosis and Treatment of Lung Cancer among People with Disabilities. Shin DW1, Cho JH2, Noh JM3, Han H4, Han K5, Park SH5, Kim SY6, Park JH7, Park JH8, Kawachi I9. .J Thorac Oncol. 2018 Nov 16. pii: S1556-0864(18)33407-5. doi: 10.1016/j.jtho.2018.10.158. [Epub ahead of print]

Alcohol consumption and lung cancer risk: A pooled analysis from the International Lung Cancer Consortium and the SYNERGY study. Brenner DR1, Fehringer G2, Zhang ZF3, et al. Cancer Epidemiol. 2018 Nov 13;58:25-32. doi: 10.1016/j.canep.2018.10.006. [Epub ahead of print]

A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. Verma V1, Sprave T2, Haque W3, Simone CB 2nd4, Chang JY5, Welsh JW5, Thomas CR Jr6. J Immunother Cancer. 2018 Nov 23;6(1):128. doi: 10.1186/s40425-018-0442-7.